1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Middlesex Water reported 2024 net income of $44.4 million and diluted EPS of $2.47, up from $31.5 million and $1.76 in 2023. Revenue rose $25.6 million to $191.9 million, driven mainly by a New Jersey base rate increase and higher weather-driven customer demand, which points to stronger earnings for shareholders.
2024 net income of $44.4 million, up $12.8 million from 2023; diluted EPS of $2.47 versus $1.76
2024 revenues of $191.9 million, up $25.6 million from $166.3 million; Middlesex System revenues rose $19.9 million on the base rate increase approved in March 2024
Fourth quarter 2024 net income of $8.8 million and diluted EPS of $0.49, versus $5.8 million and $0.32 in the fourth quarter of 2023
Board declared a first quarter 2025 dividend of $0.34 per share, payable March 3, 2025; Ocean View water utility asset purchase for about $4.6 million expected to close by April 2025
MasTec reported fourth quarter and full-year 2024 results on February 27, 2025, with revenue and GAAP net income both higher than in 2023. The company also issued initial 2025 guidance, including $13.45 billion in revenue and GAAP net income of $327 million to $366 million, and expects a GAAP net loss of $1 million in the first quarter of 2025.
Q4 2024 revenue was $3.4 billion, up from $3.3 billion; GAAP net income was $84.7 million, versus $1.2 million in Q4 2023.
Full-year 2024 GAAP net income was $199.4 million, or $2.06 per diluted share, compared with a net loss of $47.3 million in 2023.
2025 guidance: revenue of $13.45 billion, GAAP diluted EPS of $3.75 to $4.24, and adjusted EBITDA of $1.10 billion to $1.15 billion.
Estimated 18-month backlog reached a record $14.3 billion at December 31, 2024; net debt leverage ratio was 1.8x.
Ellington Financial reported net income attributable to common stockholders of $22.4 million, or $0.25 per share, for the quarter ended December 31, 2024, up from $16.2 million, or $0.19 per share, in the third quarter. Adjusted distributable earnings were $40.6 million, or $0.45 per share, which covered the $0.39 per share in dividends for the quarter. Book value per common share was $13.52 as of December 31, 2024.
Net income attributable to common stockholders of $22.4 million, or $0.25 per share, versus $16.2 million, or $0.19 per share, in the third quarter of 2024
Adjusted distributable earnings of $40.6 million, or $0.45 per share, versus $0.39 per share in dividends for the quarter
Book value per common share of $13.52 as of December 31, 2024
Monthly dividend of $0.13 per common share declared on February 10, 2025
Illinois Tool Works entered into an amendment to its Euro-denominated credit agreement with ING Bank, N.V., London Branch, as agent, on February 24, 2025. The amendment extends the termination date to February 28, 2027, with an option to extend to September 15, 2027, and lowers the interest rate spread on loans from 0.75% to 0.70%. The company's facility is fully drawn, so the change affects the cost and term of existing borrowing rather than adding available capacity.
Amendment dated February 24, 2025, to the Euro credit agreement originally dated May 5, 2023
Termination date extended to February 28, 2027; company may extend to September 15, 2027 under stated conditions
Interest rate spread on loans decreased from 0.75% to 0.70%
€750 million outstanding; facility fully drawn with no amounts available for additional borrowing
LeMaitre Vascular reported preliminary fourth-quarter 2024 results, with net sales of $55.7 million, up 14% from a year earlier, and diluted EPS of $0.49 versus $0.38. The company also gave 2025 guidance of $235.4 million to $242.8 million in sales and $2.15 to $2.32 in EPS, and raised its quarterly dividend 25% to $0.20 per share. Sales and earnings growth, plus the dividend increase and a share repurchase authorization of up to $75.0 million, are the main items for shareholders.
Q4 2024 net income was $11.2 million, versus $8.5 million in Q4 2023; operating income was $12.9 million, up 26%.
Gross margin was 69.3%, up from 68.1% in Q4 2023.
2025 full-year sales guidance is $235.4 million to $242.8 million, compared with 2024 sales of $219.9 million.
The quarterly dividend rises to $0.20 per share, payable March 27, 2025; the board authorized up to $75.0 million in buybacks through February 17, 2026.
Tidewater reported fourth-quarter 2024 revenue of $345.1 million, up from $302.7 million a year earlier, while quarterly net income of $36.9 million ($0.70 per diluted share) was roughly flat against $37.7 million ($0.70) in the prior-year quarter. The company also initiated 2025 revenue guidance of $1.32 billion to $1.38 billion and approved a new share repurchase program of up to $90.3 million, which management said is the maximum permitted under its existing debt agreements.
Q4 2024 revenue of $345.1 million, compared with $302.7 million for Q4 2023
Q4 2024 net income of $36.9 million ($0.70 per diluted share), compared with $37.7 million ($0.70) for Q4 2023
Full-year 2024 net income of $180.7 million ($3.40 per diluted share), up 85.9% from 2023
2025 guidance: revenue of $1.32 billion to $1.38 billion and gross margin of 48% to 50%; new buyback authorization of $90.3 million
Amphastar Pharmaceuticals reported fourth-quarter and full-year 2024 results on February 27, 2025. Net revenues rose 5% in the quarter and 14% for the year, and GAAP diluted EPS increased from the prior-year periods, though fourth-quarter gross margin fell to 46.5% from 54.0%.
Q4 net revenues were $186.5 million, up from $178.1 million; GAAP diluted EPS was $0.74 versus $0.68 and adjusted non-GAAP diluted EPS was $0.92 versus $0.88.
Full-year net revenues were $732.0 million, up from $644.4 million; GAAP diluted EPS was $3.06 versus $2.60.
Q4 gross margin was 46.5% versus 54.0%, mainly due to lower other revenues after the Lilly Transition Service Agreement with Lilly expired in Q4 2024; BAQSIMI product revenues were $41.8 million in the quarter.
Erie Indemnity reported fourth-quarter 2024 net income of $152.0 million, or $2.91 per diluted share, up from $110.9 million, or $2.12, a year earlier. Full-year 2024 net income rose to $600.3 million, or $11.48 per diluted share, from $446.1 million, or $8.53, in 2023. The board also declared a quarterly Class A dividend of $1.365 per share, payable April 22, 2025.
Q4 2024 net income $152.0 million, or $2.91 per diluted share, versus $110.9 million, or $2.12, in Q4 2023
Full-year 2024 net income $600.3 million, or $11.48 per diluted share, versus $446.1 million, or $8.53, in 2023
Quarterly Class A dividend of $1.365 per share (Dividend No. 379), record and ex-dividend date April 7, 2025, payable April 22, 2025
Pre-recorded webcast on the results scheduled for 10:00 a.m. ET on February 28, 2025
American Healthcare REIT reported fourth-quarter and full-year 2024 results on February 27, 2025, and issued full-year 2025 guidance. The fourth-quarter GAAP net loss per diluted share narrowed to $(0.21) from $(0.42) a year earlier, and normalized FFO per diluted share rose to $0.40 from $0.38, while full-year normalized FFO was $1.41 versus $1.40 in 2023. For 2025, the company expects normalized FFO of $1.56 to $1.60 per diluted share and total portfolio same-store NOI growth of 7.0% to 10.0%.
Q4 2024 GAAP net loss attributable to controlling interest was $(31.8) million, or $(0.21) per diluted share, versus $(27.4) million, or $(0.42), in Q4 2023.
Full-year 2024 normalized FFO was $1.41 per diluted share; total portfolio same-store NOI grew 17.7%.
2025 guidance: normalized FFO of $1.56 to $1.60 per diluted share and net income of $0.26 to $0.30 per diluted share, versus a 2024 net loss of $(0.29).
Company raised about $1.36 billion of gross equity in 2024, including $120.2 million through its at-the-market program in Q4.
Rocket Lab reported fourth-quarter 2024 revenue of $132.4 million, up from $60.0 million a year earlier, and full-year 2024 revenue of $436.2 million, up 78% from $244.6 million. The net loss widened slightly, to $52.3 million in the quarter and $190.2 million for the year, and the company guided first-quarter 2025 revenue to $117 million to $123 million.
Q4 2024 revenue was $132.4 million versus $60.0 million in Q4 2023; Q4 net loss was $52.3 million versus $50.5 million.
Full-year 2024 revenue was $436.2 million versus $244.6 million in 2023; full-year net loss was $190.2 million versus $182.6 million.
Q1 2025 guidance calls for revenue of $117 million to $123 million, with GAAP gross margins of 25% to 27%.
Electron launched 16 times in 2024, and the company reported more than $450 million in newly secured contracts.
TransMedics reported fourth-quarter and full-year 2024 results on February 27, 2025, with revenue of $121.6 million for the quarter, up 50%, and $441.5 million for the year, up 83%. The company posted full-year net income of $35.5 million, or $1.01 per diluted share, compared with a net loss of $25.0 million in 2023, and expects 2025 revenue of $530 million to $552 million.
Q4 2024 revenue of $121.6 million, up 50% from $81.2 million; Q4 net income of $6.9 million, or $0.19 per diluted share
Full-year 2024 gross margin of 59.4%, down from 63.8% in 2023; operating expenses of $224.6 million
2025 revenue outlook of $530 million to $552 million, representing 20% to 25% growth
Duolingo reported fourth-quarter and full-year 2024 results, with Q4 revenue of $209.6 million, up 39% year over year, and full-year revenue of $748.0 million, up 41%. Net income rose to $88.6 million for 2024 from $16.1 million in 2023, and the company issued initial guidance for 2025 revenue of $962.5 million to $978.5 million.
Q4 2024 revenue was $209.6 million, up 39% year over year; Q4 net income was $13.9 million, compared with $12.1 million a year earlier.
FY 2024 revenue was $748.0 million, up 41%; FY 2024 net income was $88.6 million, compared with $16.1 million in 2023.
Q4 2024 daily active users reached 40.5 million, up 51% year over year, and paid subscribers totaled 9.5 million, up 43%.
2025 guidance: bookings of $1,082 million to $1,098 million, revenue of $962.5 million to $978.5 million, and Adjusted EBITDA of $259.9 million to $274.0 million.
Bloom Energy reported fourth-quarter 2024 revenue of $572.4 million, up 60.4% from a year earlier, and record full-year 2024 revenue of $1.47 billion, up 10.5%. The company returned to a fourth-quarter GAAP net profit of $104.8 million, and its full-year 2024 GAAP net loss narrowed to $29.2 million from $302.1 million in 2023, while it issued full-year 2025 revenue guidance of $1.65 billion to $1.85 billion.
Q4 2024 revenue of $572.4 million, up 60.4% from $356.9 million in Q4 2023; Q4 GAAP net profit of $104.8 million
Full-year 2024 revenue of $1,473.9 million, up 10.5%; full-year GAAP net loss of $29.2 million, or $0.13 per share, versus a $302.1 million loss in 2023
2025 outlook: revenue of $1.65 billion to $1.85 billion, non-GAAP gross margin of about 29%, and non-GAAP operating income of $135 million to $165 million
Alignment Healthcare reported fourth-quarter and full-year 2024 results on February 27, 2025, with revenue growth of 50.7% in the quarter and 48.3% for the year. Net losses narrowed from the prior year, and the company issued 2025 guidance of $3.72 billion to $3.78 billion in revenue and $35 million to $60 million in adjusted EBITDA.
Q4 2024 total revenue was $701.2 million, up 50.7% year over year; net loss was $(31.1) million versus $(47.2) million a year earlier.
Full-year 2024 total revenue was $2,703.6 million, up 48.3%; net loss was $(128.1) million versus $(148.2) million in 2023.
2025 guidance: revenue of $3.72 billion to $3.78 billion and adjusted EBITDA of $35 million to $60 million.
Health plan membership was about 189,100 at December 31, 2024, up 58.6% year over year.
Essential Utilities reported fourth-quarter 2024 net income of $184.8 million, or $0.67 per share, up from $0.50 a year earlier, and full-year 2024 net income of $595.3 million, or $2.17 per share, up 17%. Full-year results include a gain on the sale of the Pittsburgh-area energy projects, and adjusted full-year EPS was $1.97 (non-GAAP). The company affirmed its 2025 EPS guidance of $2.07 to $2.11 and its multi-year EPS growth target of 5 to 7% a year through 2027.
Q4 2024 revenue was $604.4 million, up 26.1% from $479.4 million; Q4 net income was $184.8 million.
Full-year 2024 revenue was $2,086.1 million, up 1.6%, and net income was $595.3 million, or $2.17 per share.
Adjusted full-year 2024 EPS was $1.97 (non-GAAP), excluding one-time gains and weather-related items.
The board declared a quarterly dividend of $0.3255 per share, payable June 2, 2025, to holders of record on May 13, 2025.
Universal Health Services reported fourth-quarter 2024 net income attributable to UHS of $332.4 million, or $4.96 per diluted share, up from $216.4 million, or $3.16, a year earlier, on net revenues up 11.1% to $4.114 billion. For full-year 2024, net income was $1.142 billion, or $16.82 per diluted share, on net revenues of $15.828 billion. The company forecast 2025 net revenues of $17.020 billion to $17.364 billion and EPS-diluted of $18.45 to $19.95 per share.
Q4 2024 net income attributable to UHS: $332.4 million, or $4.96 per diluted share, versus $216.4 million, or $3.16, in Q4 2023
Q4 2024 net revenues rose 11.1% to $4.114 billion; full-year 2024 net revenues were $15.828 billion
2025 forecast: net revenues $17.020 billion to $17.364 billion; EPS-diluted $18.45 to $19.95 per share
Share repurchases in 2024 totaled approximately $598.5 million; about $824.4 million of authorization remained as of December 31, 2024
Vericel reported full-year 2024 total net revenue up 20% to $237.2 million and net income of $10.4 million, or $0.20 per diluted share, compared with a net loss of $3.2 million in 2023. The company reaffirmed 2025 total net revenue growth guidance of 20% to 23% and increased its mid-term profitability targets for 2029, which matters to shareholders because it shows continued growth and a shift to profitability.
Full-year 2024 total net revenue rose 20% to $237.2 million, including $197.3 million of MACI net revenue.
Full-year 2024 net income was $10.4 million, or $0.20 per diluted share, versus a net loss of $3.2 million in 2023.
2025 guidance reaffirmed: total net revenue growth of 20% to 23%, gross margin of 73% to 74%, and adjusted EBITDA margin of 25% to 26%.
Mid-term targets increased: gross margin in the high-70% range and adjusted EBITDA margin in the high-30% range by 2029.
Frontdoor reported full-year 2024 revenue up 4% to $1.84 billion, net income up 37% to $235 million, and diluted earnings per share up 42% to $3.01. For 2025, it projects revenue of $2.0 billion to $2.04 billion and Adjusted EBITDA of $450 million to $475 million, including the 2-10 Home Buyers Warranty acquisition.
Full-year 2024 Adjusted EBITDA rose 28% to $443 million, and gross profit margin expanded 410 basis points to 54%.
Fourth-quarter 2024 revenue rose 5% to $383 million, while net income was flat at $9 million.
The 2025 outlook includes a gross profit margin of 51.5% to 53% and Adjusted EBITDA of $450 million to $475 million.
The company repurchased $160 million of shares in 2024 and will hold a 2025 Investor Day on February 27, 2025.
Installed Building Products reported fourth-quarter 2024 net revenue up 4.1% to a record $750.2 million, with net income up 3.1% to $66.9 million, or $2.39 per diluted share. For the full year, net revenue rose 5.9% to a record $2.9 billion and diluted EPS rose to $9.10 from $8.61, and the Board approved a 6% higher quarterly dividend and a $1.70 annual variable dividend payable March 31, 2025.
Q4 2024 net income $66.9 million, or $2.39 per diluted share, versus $64.9 million, or $2.29, a year earlier
Full-year 2024 net income $256.6 million, or $9.10 per diluted share, versus $8.61 in 2023
Quarterly cash dividend of $0.37 per share and annual variable dividend of $1.70 per share, payable March 31, 2025 to holders of record March 14, 2025
New stock repurchase program of up to $500 million, expiring March 1, 2026
Hayward Holdings reported fourth-quarter 2024 net sales up 17% to $327.1 million, with net income up 76% to $54.7 million and diluted EPS of $0.25. For fiscal 2025 it expects net sales of $1.060 billion to $1.100 billion and adjusted EBITDA of $280 million to $290 million, compared with $277.4 million of adjusted EBITDA in fiscal 2024.
Q4 2024 net sales rose 17% to $327.1 million; net income rose 76% to $54.7 million
Q4 2024 diluted EPS was $0.25, up 79%; adjusted diluted EPS was $0.27, up 35%
Full-year 2024 net sales rose 6% to $1,051.6 million; net income rose 47% to $118.7 million
2025 guidance: net sales of $1.060 billion to $1.100 billion; adjusted EBITDA of $280 million to $290 million
Nexstar Media Group reported record fourth-quarter 2024 net revenue of $1.49 billion, up 14.1%, driven mainly by election-year political advertising, and net income of $229 million compared with $100 million a year earlier. The company also issued 2025 Adjusted EBITDA guidance of $1.5 billion to $1.595 billion. The filing does not compare this guidance with prior expectations.
Q4 net revenue of $1.49 billion, up 14.1%; advertising revenue of $758 million, up 29.6%, including $254 million of political advertising
Q4 net income of $229 million versus $100 million; Adjusted EBITDA of $628 million, up 39.9%
2025 Adjusted EBITDA guidance range of $1.5 billion to $1.595 billion
Returned $820 million to shareholders and repaid $327 million of debt in 2024
Evergy reported fourth-quarter 2024 GAAP earnings of $78.2 million, or $0.34 per share, up from $58.0 million, or $0.25 per share, a year earlier. The company reaffirmed its 2025 GAAP and adjusted EPS guidance of $3.92 to $4.12, and raised its 2025-2029 capital investment plan to $17.5 billion, which shareholders will watch for its effect on future earnings growth.
Full-year 2024 GAAP EPS was $3.79, compared with $3.17 in 2023; adjusted EPS (non-GAAP) was $3.81, compared with $3.54.
Adjusted 2024 EPS of $3.81 was within the company's guidance range of $3.73 to $3.93, according to Chairman and CEO David Campbell.
Evergy declared a quarterly dividend of $0.6675 per share, payable March 21, 2025, to holders of record as of March 10, 2025.
The company reaffirmed a long-term adjusted EPS growth target of 4% to 6% through 2029 and expects growth in the upper half of that range beginning in 2026.
PENN Entertainment reported fourth-quarter 2024 revenue of $1,669.0 million, up from $1,395.4 million a year earlier, and a net loss of $133.8 million, narrowed from $358.8 million. The company also said it intends to repurchase at least $350 million of shares in 2025, which matters to shareholders because it signals a large capital return alongside improved results.
Q4 2024 diluted loss per share was $(0.88), compared with $(2.37) in Q4 2023.
Adjusted EBITDA was $165.2 million, compared with a loss of $(39.6) million in the prior-year quarter.
Interactive segment revenue was $275.0 million, compared with $31.5 million a year earlier, including a tax gross-up of $132.8 million.
Full-year 2024 net loss was $313.3 million, compared with $491.4 million in 2023.
TechnipFMC reported fourth-quarter 2024 revenue of $2,367.3 million, up 13.9% from a year earlier, and net income of $224.7 million, or $0.52 per diluted share, up from $0.12 a year earlier but down 18.2% from the prior quarter. The company raised its 2025 subsea revenue guidance to $8.4-8.8 billion and said 2025 shareholder distributions would grow at least 30%, which matters to shareholders because it signals higher expected revenue and cash returns. Net income included a discrete non-cash tax benefit of $54 million.
Q4 2024 revenue was $2,367.3 million, up 13.9% year over year, and adjusted diluted EPS was $0.54, versus $0.14 a year earlier.
Subsea 2025 revenue guidance was raised to $8.4-8.8 billion from $8.3-8.7 billion; subsea adjusted EBITDA margin guidance is 19-20%, up from 18.5-20%.
Net income included a discrete non-cash tax benefit of $54 million; the company returned $486 million to shareholders in 2024.
Management expects 2025 shareholder distributions to be at least 70% of free cash flow, driving growth of at least 30% year over year.
Life Time Group Holdings reported fourth-quarter 2024 revenue of $663.3 million, up 18.7%, and net income of $37.2 million, up 57.0%. For the full year, revenue rose 18.2% to $2,621.0 million and net income more than doubled to $156.2 million, and the company raised its 2025 outlook based on early 2025 results.
Net debt leverage ratio improved to 2.28x at December 31, 2024, from 3.61x a year earlier
2025 guidance: revenue $2,925 million to $2,975 million, net income $277 million to $284 million, adjusted EBITDA $780 million to $800 million, all raised from January 16, 2025 guidance
Full-year free cash flow of $273.6 million, including $207.4 million of sale-leaseback proceeds
Warby Parker reported fourth quarter and full year 2024 results on February 27, 2025, with net revenue up 17.8% in the quarter and 15.2% for the year. The company also gave 2025 guidance of $878 million to $893 million in net revenue, but still posted a full year 2024 GAAP net loss of $20.4 million.
Full year 2024 net revenue rose $101.6 million, or 15.2%, to $771.3 million; fourth quarter net revenue rose 17.8% to $190.6 million.
Full year 2024 GAAP net loss narrowed $42.8 million to $20.4 million; fourth quarter GAAP net loss was $6.9 million.
Full year 2024 Adjusted EBITDA rose $20.8 million to $73.1 million, a 9.5% margin.
2025 guidance: net revenue of $878 million to $893 million and Adjusted EBITDA of about $97 million at the revenue midpoint, with 45 planned new stores.
Acushnet reported full-year 2024 net sales of $2.46 billion, up 3.2%, and net income attributable to the company of $214.3 million, up $15.9 million, with fourth-quarter net loss narrowing to $1.1 million from $26.8 million a year earlier. The company also gave a 2025 outlook of $2.49 billion to $2.54 billion in net sales and $405 million to $420 million in Adjusted EBITDA, and raised its quarterly dividend 9.3% and added a $250.0 million share repurchase authorization.
Full-year 2024 Adjusted EBITDA was $404.4 million, up 7.5%, and fourth-quarter Adjusted EBITDA was $12.4 million versus a $1.5 million loss a year earlier
2025 outlook calls for net sales of $2,485 million to $2,535 million and Adjusted EBITDA of $405 million to $420 million, including an estimated negative currency impact of about $35 million
Quarterly cash dividend increased 9.3% to $0.235 per share, payable March 21, 2025 to holders of record as of March 7, 2025
On February 13, 2025, the board authorized an additional $250.0 million in share repurchases, bringing the total authorization to $1.25 billion
LifeStance Health Group reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue grew 19% for the full year to $1.25 billion, and the full-year net loss narrowed to $57.4 million from $186.3 million in 2023. The company also expects 2025 revenue of $1.40 billion to $1.44 billion and Adjusted EBITDA of $130 million to $150 million.
Q4 2024 revenue was $325.5 million, up 16%; full-year revenue was $1.25 billion, up 19%.
Q4 2024 net loss was $7.1 million versus $45.0 million a year earlier; full-year net loss was $57.4 million versus $186.3 million.
Full-year 2024 Adjusted EBITDA was $119.7 million, up 103%; Free Cash Flow was $85.7 million.
2025 guidance: revenue of $1.40 billion to $1.44 billion, Center Margin of $440 million to $464 million, Adjusted EBITDA of $130 million to $150 million; Q1 2025 revenue of $320 million to $340 million.
Bristow Group reported fourth quarter and full-year 2024 results. Full-year net income rose to $94.8 million and Adjusted EBITDA of $236.8 million beat the top of its raised outlook, while fourth-quarter revenue fell from the prior quarter. The company also set a new $125 million share repurchase program, plans a quarterly dividend starting in Q1 2026, and intends to reduce gross debt to about $500 million by the end of 2026.
Full-year 2024 net income was $94.8 million, or $3.21 per diluted share, compared with a net loss of $6.8 million in 2023; total revenues were $1.4 billion versus $1.3 billion.
Fourth-quarter 2024 revenues were $353.5 million, down from $365.1 million in the third quarter, while diluted earnings per share rose to $1.07 from $0.95.
Full-year 2024 Adjusted EBITDA was $236.8 million, above the previously upward revised outlook range of $220 million to $230 million.
The company issued 2025 guidance of $1.420 billion to $1.615 billion in total revenues and $230 million to $260 million in Adjusted EBITDA, and plans a $0.125 per share quarterly dividend beginning in Q1 2026.
Innovex reported fourth-quarter 2024 revenue of $251 million, up 89% year-over-year, and adjusted EBITDA of about $49 million, up $17 million from a year earlier, with the Dril-Quip merger and DWS acquisition driving the gains. The board authorized a $100 million share repurchase program, and the company guided first-quarter 2025 adjusted EBITDA to $45 million to $50 million and revenue to $245 million to $255 million.
Q4 2024 revenue was $251 million, up 89% year-over-year and 65% sequentially; full-year 2024 revenue was $661 million, up 19%.
Q4 2024 adjusted EBITDA was about $49 million; free cash flow was $29 million.
Board authorized a $100 million share repurchase program.
Q1 2025 guidance: adjusted EBITDA of $45 million to $50 million and revenue of $245 million to $255 million.
Morningstar reported fourth-quarter 2024 revenue up 9.7% to $591.0 million and full-year 2024 revenue up 11.6% to $2.3 billion. Fourth-quarter diluted EPS rose to $2.71 from $1.71, including a $64.0 million gain on the sale of US TAMP assets, while adjusted diluted EPS rose 8.6% to $2.14. Revenue and profit both improved, although the adjusted operating margin slipped to 20.6% from 21.0%.
Q4 2024 revenue was $591.0 million, up 9.7% on a reported basis and 10.6% on an organic basis.
Q4 diluted EPS was $2.71 versus $1.71; the $64.0 million gain on the sale of US TAMP assets added $1.10 per share.
Q4 adjusted diluted EPS was $2.14, up 8.6%, and adjusted operating margin was 20.6% versus 21.0%.
Full-year 2024 diluted EPS was $8.58 versus $3.29, and free cash flow rose 127.5% to $448.9 million.
Chesapeake Utilities reported full-year 2024 net income of $118.6 million, or $5.26 per diluted share, up from $87.2 million, or $4.73, in 2023. Adjusted EPS of $5.39 was in line with its previously announced guidance range, and the company reaffirmed its 2025 EPS guidance of $6.15 to $6.35 per share, which matters to shareholders because it signals the company expects to keep growing earnings. Growth was driven largely by the Florida City Gas acquisition, though higher interest expense and additional shares outstanding partly offset the gains.
Full-year 2024 net income was $118.6 million ($5.26 per diluted share), compared with $87.2 million ($4.73) in 2023.
Full-year 2024 adjusted EPS was $5.39, compared with $5.31 in 2023, excluding Florida City Gas transaction and transition-related expenses.
Fourth-quarter 2024 net income was $36.7 million ($1.60 per share), compared with $25.3 million ($1.26) a year earlier; adjusted EPS was $1.63 versus $1.64.
The company reaffirmed 2025 EPS guidance of $6.15 to $6.35 per share and 2024 capital expenditures totaled $356 million.
Chemed reported fourth-quarter 2024 revenue of $640.0 million, up 9.2%, with GAAP diluted EPS of $6.02, up 2.0%, and adjusted diluted EPS of $6.83, up 3.5%. The company guided to full-year 2025 adjusted diluted EPS of $24.95 to $25.45, compared with $23.13 in 2024, while Roto-Rooter revenue and adjusted EBITDA declined in the quarter.
Q4 2024 revenue $640.0 million, up 9.2%; VITAS net patient revenue up 17.4% to $411.0 million
Roto-Rooter Q4 revenue fell 2.9% to $229.0 million and adjusted EBITDA fell 7.2% to $60.3 million
2025 guidance: adjusted diluted EPS of $24.95 to $25.45 versus $23.13 for 2024; Roto-Rooter revenue growth of 2.4% to 3.0%
Repurchased 388,235 shares for $212.8 million in the quarter; about $255.3 million of authorization remained at December 31, 2024
Certara reported fourth-quarter 2024 revenue of $100.4 million, up 14% from a year earlier, and net income of $6.6 million, compared with a net loss of $12.5 million in the prior-year quarter. The company also issued full-year 2025 guidance, forecasting revenue of $415 million to $425 million and adjusted diluted EPS of $0.42 to $0.46.
Q4 2024 revenue was $100.4 million, up 14%; software revenue rose 26% to $42.3 million
Q4 2024 diluted EPS was $0.04 versus a loss of $0.08; adjusted EBITDA was $33.5 million, up 13%
2025 guidance: revenue of $415 million to $425 million and adjusted EBITDA margin of 30% to 32%
Full-year 2024 net loss narrowed to $12.1 million from $55.4 million in 2023
CRH reported fourth-quarter and full-year 2024 results on February 26, 2025. Full-year revenue was $35.6 billion, up 2%, while net income rose 15% to $3.5 billion and basic EPS rose 16% to $5.06. The company also guided 2025 net income to $3.7 billion to $4.1 billion and adjusted EBITDA to $7.3 billion to $7.7 billion, and it raised the quarterly dividend to $0.37.
FY 2024 total revenues $35.6 billion, up 2%; net income $3.5 billion, up 15%; adjusted EBITDA $6.9 billion, up 12%
FY 2024 basic EPS $5.06, up 16%; Q4 2024 basic EPS $1.03, up 4%
2025 guidance: net income $3.7 billion to $4.1 billion; adjusted EBITDA $7.3 billion to $7.7 billion; diluted EPS $5.34 to $5.80
Quarterly dividend increased to $0.37 per share; new $0.3 billion share buyback tranche to be completed by May 2, 2025; net debt rose to $10.5 billion
Rush Street Interactive reported fourth-quarter 2024 revenue of $254.2 million, up 31% year over year, and net income of $6.5 million compared with a net loss of $5.5 million a year earlier. For full-year 2024, revenue rose 34% to $924.1 million and net income was $7.2 million, versus a net loss of $60.1 million in 2023. The company also initiated 2025 guidance of $1,010 million to $1,080 million in revenue and $115 million to $135 million in Adjusted EBITDA.
Q4 2024 revenue was $254.2 million, up 31% from $193.9 million; net income was $6.5 million versus a net loss of $5.5 million in Q4 2023.
Full-year 2024 revenue was $924.1 million, up 34%, and net income was $7.2 million versus a net loss of $60.1 million in 2023.
2025 guidance: revenue of $1,010 million to $1,080 million and Adjusted EBITDA of $115 million to $135 million, with no prior guidance to compare against.
Q4 2024 Adjusted EBITDA was $30.6 million versus $11.5 million a year earlier; unrestricted cash and cash equivalents were $229 million at December 31, 2024.
Acadia Pharmaceuticals reported fourth-quarter and full-year 2024 results, with total revenue of $957.8 million for the year and net income of $226.5 million, compared with a net loss of $61.3 million in 2023. The full-year profit includes a one-time $146.5 million gain from the sale of a rare pediatric disease priority review voucher. The company also gave full-year 2025 total revenue guidance of $1.03 billion to $1.095 billion.
Full-year 2024 net product sales were $957.8 million, up 32%, with NUPLAZID at $609.4 million and DAYBUE at $348.4 million.
Fourth-quarter 2024 net income was $143.7 million, or $0.86 per diluted share, compared with $45.8 million, or $0.28 per share, a year earlier.
2025 guidance calls for total revenue of $1.03 billion to $1.095 billion, with NUPLAZID net sales of $650 million to $690 million and DAYBUE net sales (U.S. only) of $380 million to $405 million.
Cash, cash equivalents and investment securities were $756.0 million at December 31, 2024, up from $438.9 million a year earlier.
Invitation Homes reported fourth-quarter and full-year 2024 results, with revenue and Core FFO per share both higher than a year earlier. For 2025, the company guided to Core FFO of $1.88 to $1.94 per share, with a midpoint of $1.91 compared with $1.88 in 2024, but expects Same Store NOI growth of 1.00% to 3.00%, below the 4.6% it reported for 2024.
Q4 2024 total revenues rose 5.6% to $659 million; net income per diluted share was $0.23, versus $0.21 in Q4 2023.
Q4 2024 Core FFO per share rose 5.9% to $0.47, while FFO per share fell to $0.36 from $0.41.
FY 2025 Core FFO per share guidance is $1.88 to $1.94, compared with $1.88 reported for FY 2024.
FY 2025 Same Store NOI growth guidance is 1.00% to 3.00%, versus 4.6% in FY 2024.
Green Brick Partners reported record full-year 2024 total revenues of $2.1 billion, up 18.1%, and diluted EPS of $8.45, up 37.6%. Fourth-quarter total revenues were $567.3 million, up 26.0%, and diluted EPS was $2.31, up 46.2%. On February 17, 2025, the board approved raising the share repurchase authorization to $100 million.
Full-year 2024 total revenues were $2.10 billion, up 18.1% from 2023; diluted EPS was $8.45, up 37.6%.
Fourth-quarter 2024 total revenues were $567.3 million, up 26.0%; diluted EPS was $2.31, up 46.2%.
Full-year homebuilding gross margin was 33.8%, up 290 basis points; debt to total capital was 17.2% at year-end.
On February 17, 2025, the board increased the share repurchase authorization to $100 million.
EVERTEC reported fourth quarter 2024 revenue of $216.4 million, up 11.2%, and GAAP net income attributable to common shareholders of $40.1 million, or $0.62 per diluted share, compared with $11.5 million, or $0.17, a year earlier. The company also gave 2025 guidance calling for revenue of $889 million to $899 million and adjusted earnings per share of $3.34 to $3.45, both above 2024 levels.
Q4 2024 revenue was $216.4 million, up from $194.6 million in Q4 2023, including a one-time $0.6 million revenue item in Latin America.
Q4 2024 GAAP net income attributable to common shareholders was $40.1 million, or $0.62 per diluted share, including an $8.9 million net gain from the sale of tax credits.
Full year 2024 revenue was $845.5 million, up 22%, and GAAP net income attributable to common shareholders was $112.6 million, or $1.73 per diluted share.
2025 outlook: revenue of $889 million to $899 million and adjusted earnings per share of $3.34 to $3.45, versus $3.28 in 2024.
Tandem Diabetes reported fourth-quarter and full-year 2024 results and gave 2025 guidance. GAAP sales rose 26% for the year to $940.2 million, and the net loss narrowed to $96.0 million from $222.6 million. The company expects 2025 sales of approximately $997 million to $1.007 billion, with adjusted EBITDA margin of about 3 percent for the full year.
Q4 2024 GAAP sales grew 44% to $282.6 million; non-GAAP sales grew 21% to $252.4 million, with GAAP results affected by the Tandem Choice program.
Q4 2024 GAAP net income was $0.8 million, or $0.01 per share, compared with a net loss of $30.0 million, or $0.46 per share, a year earlier.
Full-year 2024 GAAP net loss was $96.0 million, or $1.47 per share, compared with $222.6 million, or $3.43 per share, in 2023.
2025 guidance: full-year sales of approximately $997 million to $1.007 billion and first-quarter sales of approximately $219 million to $224 million.
eBay reported fourth-quarter 2024 revenue of $2.6 billion, up 1%, and GMV of $19.3 billion, up 4%. Non-GAAP earnings per diluted share rose 16% to $1.25, while GAAP EPS was flat at $1.40. The company also guided first-quarter 2025 revenue to $2.52 billion to $2.56 billion and declared a $0.29 quarterly dividend.
Q4 2024 revenue $2.6 billion, up 1%; GMV $19.3 billion, up 4%
GAAP EPS $1.40, unchanged from Q4 2023; non-GAAP EPS $1.25, up from $1.07
Full-year 2024 GAAP EPS $3.95, down 24% from $5.21
Q1 2025 guidance: revenue $2.52 billion to $2.56 billion; non-GAAP EPS $1.32 to $1.36
Corcept Therapeutics reported fourth-quarter and full-year 2024 results and gave a corporate update in a press release attached to this 8-K. Full-year 2024 revenue rose to $675.0 million from $482.4 million and full-year net income rose to $141.2 million, while fourth-quarter net income and diluted earnings per share were slightly lower than a year earlier. The company also gave 2025 revenue guidance of $900-950 million.
Q4 2024 revenue was $181.9 million, compared with $135.4 million in Q4 2023.
Q4 2024 net income was $30.7 million, or $0.26 diluted per share, versus $31.4 million, or $0.28, in Q4 2023.
Full-year 2024 net income was $141.2 million, or $1.23 diluted per share, versus $106.1 million, or $0.94, in 2023.
Cash and investments were $603.2 million at December 31, 2024; company expects ROSELLA pivotal trial data in the current quarter.
Dorman Products reported fourth quarter 2024 net sales of $533.8 million, up 8.0%, and diluted EPS of $1.77, up 11%. For full year 2024, net sales were $2.0 billion, up 4.1%, and diluted EPS was $6.14, up 50%. The company also issued 2025 guidance calling for net sales growth of 3% to 5% and diluted EPS of $7.00 to $7.30.
Q4 2024 net sales $533.8 million, up 8.0%; Q4 diluted EPS $1.77, up 11% from $1.60
Full year 2024 net sales $2,009.2 million, up 4.1%; full year diluted EPS $6.14, up 50%
2025 guidance: net sales growth 3% to 5%; diluted EPS $7.00 to $7.30; adjusted diluted EPS $7.55 to $7.85
Conference call and webcast scheduled for February 27, 2025 at 8:00 a.m. Eastern time
LegalZoom reported fourth-quarter and full-year 2024 results and gave 2025 guidance of about 5% revenue growth and an Adjusted EBITDA margin of about 23%. Quarterly revenue rose 2% and net income rose 74%, while full-year net income rose 115% to $30.0 million, which shows higher profit on modest sales growth.
Q4 2024 revenue was $161.7 million, up 2% year-over-year; subscription revenue was $108.7 million, up 2%.
Q4 2024 net income was $12.9 million, or $0.07 per share, compared with $7.4 million in Q4 2023.
Full-year 2024 revenue was $681.9 million, up 3%, and full-year Adjusted EBITDA was $148.1 million, up 25%.
Guidance: Q1 2025 revenue of $175 million to $179 million and Adjusted EBITDA of $33 million to $36 million; full-year 2025 revenue growth of about 5%.
Nutanix reported second-quarter fiscal 2025 results for the period ended January 31, 2025, with revenue of $654.7 million, up 16% from $565.2 million a year earlier, and GAAP net income of $56.4 million, up from $32.8 million. The company also gave revenue guidance of $620 million to $630 million for the third quarter and $2.495 billion to $2.515 billion for fiscal 2025, which shareholders can compare with future results.
Annual recurring revenue reached $2.06 billion, up 19% year over year
GAAP diluted earnings per share were $0.19, compared with $0.12 a year earlier
Free cash flow was $187.1 million, compared with $162.6 million a year earlier
Third-quarter revenue outlook is $620 million to $630 million; fiscal 2025 revenue outlook is $2.495 billion to $2.515 billion
EMCOR reported record fourth-quarter and full-year 2024 revenues, diluted EPS and operating income, with fourth-quarter revenue up 9.6% to $3.77 billion and diluted EPS of $6.32. The company guided 2025 diluted EPS to $22.25 to $24.00 and increased its share repurchase authorization by $500 million.
Q4 2024 diluted EPS of $6.32 versus $4.47 a year earlier; full-year 2024 diluted EPS of $21.52 versus $13.31
Full-year 2024 revenues of $14.57 billion, up 15.8%; operating income of $1.34 billion, or 9.2% of revenues
2025 guidance: revenues of $16.1 billion to $16.9 billion, operating margin of 8.5% to 9.2%, diluted EPS of $22.25 to $24.00
Board authorized an additional $500 million for share repurchases under the existing program, which has no expiration date
Graham Holdings reported fourth-quarter 2024 revenue of $1.2 billion, up 7%, and diluted earnings per share of $125.55, compared with $11.72 a year earlier. The EPS figure includes a one-time, noncash $653.4 million pension settlement gain; excluding certain items, fourth-quarter EPS was $22.58 versus $10.94. On February 25, 2025, the company also agreed to settle a significant portion of a mandatorily redeemable noncontrolling interest for $205 million.
Q4 2024 revenue was $1,245.8 million, up 7% from $1,166.8 million; operating income was $72.5 million versus $40.8 million.
Q4 diluted EPS was $125.55 versus $11.72; excluding certain items, EPS was $22.58 versus $10.94.
A $653.4 million pre-tax, noncash pension settlement gain was recorded in Q4 2024 after a group annuity purchase; the February 25, 2025 settlement totals $205 million, including $186.25 million in cash and $18.75 million in Class B stock.
APi Group reported fourth-quarter 2024 net revenues of $1.9 billion, up 5.8%, and net income of $67 million, up from $25 million a year earlier. For full-year 2025 it gave initial guidance of $7.3 billion to $7.5 billion in net revenues and $970 million to $1.02 billion in adjusted EBITDA, compared with $7.0 billion and $893 million in 2024. Shareholders get a view of expected 2025 growth, though full-year 2024 organic revenue fell 0.9%.
Q4 2024 net revenues $1,861 million, up 5.8% (1.3% organic); adjusted EBITDA $242 million, up 16.3%
Q4 2024 GAAP net income $67 million vs. $25 million; diluted EPS $(0.10) vs. $(1.08)
Q4 2024 adjusted diluted EPS $0.51 vs. $0.44 a year earlier, up 15.9%
2025 guidance: net revenues $7,300-$7,500 million; adjusted EBITDA $970-$1,020 million; Q1 2025 adjusted EBITDA $185-$195 million
Vita Coco reported fourth-quarter and full-year 2024 results, with net sales up 5% for the year to $516 million and net income up to $56 million. The company guided 2025 net sales to $555-570 million and Adjusted EBITDA to $86-92 million, which points to continued growth if met, though fourth-quarter net income fell from the prior year.
Q4 2024 net sales rose 20% to $127 million, but Q4 net income fell to $3 million ($0.06 per diluted share) from $7 million ($0.11).
Full-year 2024 net income rose to $56 million ($0.94 per diluted share) from $47 million ($0.79), and Adjusted EBITDA rose to $84 million from $68 million.
2025 outlook: net sales of $555-570 million, gross margin of 35-37%, and Adjusted EBITDA of $86-92 million; the outlook excludes any impact from potential tariffs.
Cash and cash equivalents were $165 million at December 31, 2024, with no debt outstanding.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.